Clinical Trials Logo
  1. Home
  2. Indolent Lymphoma
  3. NCT00954005

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma — R-GO  

Indolent Lymphoma Clinical Trial

Official title:
Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma

Clinical Trial Summary

The purpose of the phase I part is to determine the tolerability, the initial safety profile and maximum tolerated dose of oxaliplatin in combination with gemcitabine for indolent lymphoma. In the phase II part the investigators want to estimate the activity of gemcitabine and oxaliplatin in combination with rituximab for patients with relapsed/refractory indolent lymphoma.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00954005
Study type Interventional
Source German Low Grade Lymphoma Study Group
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date January 2003
Completion date June 2012
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03261349 - Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma Phase 2
Active, not recruiting NCT03133221 - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Phase 2
Recruiting NCT05003141 - PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies Phase 1
Recruiting NCT00687778 - 11C-Acetate PET/CT Non-FDG-Avid Tumors N/A
Recruiting NCT05543070 - Low-dose Radiotherapy in iNHL Phase 2
Active, not recruiting NCT04431635 - Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma Phase 1
Completed NCT00980395 - Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma Phase 2
Recruiting NCT04957693 - Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period N/A
Completed NCT03424603 - Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Phase 1
Completed NCT01263899 - A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies Phase 2
Recruiting NCT05020678 - NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Phase 1
Active, not recruiting NCT04806035 - Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Phase 1